Dendritic cells in the cross hair for the generation of Tailored Vaccines

Frontiers in Immunology

Volumn 9, Issue JUN, 2018, Pages

  Gornati, Laura ^a   Zanoni, Ivan ^a,b   Granucci, Francesca ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adjuvants; Antigen delivery; Dendritic cells; Pattern recognition receptors; Vaccination

Indexed keywords

ADJUVANT; VACCINE;

ANTIGEN PRESENTING CELL; DENDRITIC CELL; HAIR; IMMUNOLOGICAL TOLERANCE; MALIGNANT NEOPLASM; REVIEW; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 85049080674     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01484     Document Type: Review

References (180)

1. Russell CD. Eradicating infectious disease: can we and should we? Front Immunol (2011) 2:1-3. doi:10.3389/fimmu.2011.00053
2. Finlay BB, McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell (2006) 124(4):767-82. doi:10.1016/j.cell.2006.01.034
3. Davenne T, McShane H. Why don't we have an effective tuberculosis vaccine yet? Expert Rev Vaccines (2016) 15(8):1009-13. doi:10.1586/14760584.2016.1170599
4. Sahay B, Nguyen CQ, Yamamoto JK. Conserved HIV epitopes for an effective HIV vaccine. J Clin Cell Immunol (2017) 8(4):518. doi:10.4172/2155-9899.1000518
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature (1998) 392:245-52. doi:10.1038/32588
7. Steinman RM, Chon ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 137:1142-62. doi:10.1084/jem.137.5.1142
8. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lympoid organs of mice. II. Functional properties in vitro. J Exp Med (1974) 139:380-97. doi:10.1084/jem.139.2.380
9. Granot T, Senda T, Carpenter DJ, Matsuoka N, Weiner J, Gordon CL, et al. Dendritic cells display subset and tissue-specific maturation dynamics over human life. Immunity (2017) 46(3):504-15. doi:10.1016/j.immuni.2017.02.019
10. Guilliams M, Dutertre CA, Scott CL, McGovern N, Sichien D, Chakarov S, et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity (2016) 45(3):669-84. doi:10.1016/j.immuni.2016.08.015
11. Elpek KG, Bellemare-Pelletier A, Malhotra D, Reynoso ED, Lukacs-Kornek V, DeKruyffRH, et al. Lymphoid organ-resident dendritic cells exhibit unique transcriptional fingerprints based on subset and site. PLoS One (2011) 6(8):e23921. doi:10.1371/journal.pone.0023921
12. Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science (2017) 356(6335):eaah4573. doi:10.1126/science.aah4573
13. Heidkamp GF, Sander J, Lehmann CHK, Heger L, Eissing N, Baranska A, et al. Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment. Sci Immunol (2016) 1(6):eaai7677. doi:10.1126/sciimmunol.aai7677
14. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol (2013) 31(1):563-604. doi:10.1146/annurev-immunol-020711-074950
15. Alcántara-Hernández M, Leylek R, Wagar LE, Engleman EG, Keler T, Marinkovich MP, et al. High-dimensional phenotypic mapping of human dendritic cells reveals interindividual variation and tissue specialization. Immunity (2017) 47(6):1037-50.e6. doi:10.1016/j.immuni.2017.11.001
16. See P, Dutertre CA, Chen J, Günther P, McGovern N, Irac SE, et al. Mapping the human DC lineage through the integration of high-dimensional techniques. Science (2017) 356(6342):eaag3009. doi:10.1126/science.aag3009
17. Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity (2014) 40(5):642-56. doi:10.1016/j.immuni.2014.04.016
18. Segura E, Valladeau-Guilemond J, Donnadieu M-H, Sastre-Garau X, Soumelis V, Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med (2012) 209(4):653-60. doi:10.1084/jem.20111457
19. Kashem SW, Igyarto BZ, Gerami-Nejad M, Kumamoto Y, Mohammed JA, Jarrett E, et al. Candida albicans morphology and dendritic cell subsets determine T helper cell differentiation. Immunity (2015) 42(2):356-66. doi:10.1016/j.immuni.2015.01.008
20. Igyártó BZ, Haley K, Ortner D, Bobr A, Gerami-Nejad M, Edelson BT, et al. Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses. Immunity (2011) 35(2):260-72. doi:10.1016/j.immuni.2011.06.005
21. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell (2010) 140(6):805-20. doi:10.1016/j.cell.2010.01.022
22. Ivanov S, Scallan JP, Kim KW, Werth K, Johnson MW, Saunders BT, et al. CCR7 and IRF4-dependent dendritic cells regulate lymphatic collecting vessel permeability. J Clin Invest (2016) 126(4):1581-91. doi:10.1172/JCI84518
23. Förster R, Braun A, Worbs T. Lymph node homing of T cells and dendritic cells via afferent lymphatics. Trends Immunol (2012) 33(6):271-80. doi:10.1016/j.it.2012.02.007
24. Braun A, Worbs T, Moschovakis GL, Halle S, Hoffmann K, Bölter J, et al. Afferent lymph-derived T cells and DCs use different chemokine receptor CCR7-dependent routes for entry into the lymph node and intranodal migration. Nat Immunol (2011) 12(9):879-87. doi:10.1038/ni.2085
25. Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, Rudensky AY, et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity (2003) 19(1):47-57. doi:10.1016/S1074-7613(03)00175-4
26. Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J, et al. Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood (2012) 120(6):1237-45. doi:10.1182/blood-2011-09-379776
27. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 194(6):769-80. doi:10.1084/jem.194.6.769
28. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol (2003) 21(1):685-711. doi:10.1146/annurev.immunol.21.120601.141040
29. Kolls JK. Th17 cells in mucosal immunity and tissue inflammation. Semin Immunopathol (2010) 32(1):1-2. doi:10.1007/s00281-010-0198-8
30. Zanoni I, Ostuni R, Capuano G, Collini M, Caccia M, Ronchi AE, et al. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature (2009) 460(7252):264-8. doi:10.1038/nature08118
31. Chen M, Wang YH, Wang Y, Huang L, Sandoval H, Liu YJ, et al. Dendritic cell apoptosis in the maintenance of immune tolerance. Science (2006) 311(5764):1160-4. doi:10.1126/science.1122545
32. Stranges PB, Watson J, Cooper CJ, Choisy-Rossi CM, Stonebraker AC, Beighton RA, et al. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity (2007) 26(5):629-41. doi:10.1016/j.immuni.2007.03.016
33. Tubo NJ, Fife BT, Pagan AJ, Kotov DI, Goldberg MF, Jenkins MK. Most microbe-specific naïve CD4+ T cells produce memory cells during infection. Science (2016) 351(6272):511-5. doi:10.1126/science.aad0483
34. Wen Y, Shi Y. Alum: an old dog with new tricks. Emerg Microbes Infect (2016) 5(3):e25. doi:10.1038/emi.2016.40
35. Kool M, Pétrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M, et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol (2008) 181(6):3755-9. doi:10.4049/jimmunol.181.6.3755
36. Li H, Willingham SB, Ting JP-Y, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol (2008) 181(1):17-21. doi:10.4049/jimmunol.181.1.17
37. Franchi L, Núñez G. The Nlrp3 inflammasome is critical for aluminum hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity. Eur J Immunol (2008) 38(8):2085-9. doi:10.1002/eji.200838549
38. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med (2011) 17(8):996-1002. doi:10.1038/nm.2403
39. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, et al. Adjuvant-enhanced antibody receptor signaling. Science (2006) 314:1936-8. doi:10.1126/science.1135299
40. McKee AS, Munks MW, MacLeod MKL, Fleenor CJ, Van Rooijen N, Kappler JW, et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol (2009) 183(7):4403-14. doi:10.4049/jimmunol.0900164
41. Khameneh HJ, Ho AWS, Spreafico R, Derks H, Quek HQY, Mortellaro A. The Syk-NFAT-IL-2 pathway in dendritic cells is required for optimal sterile immunity elicited by alum adjuvants. J Immunol (2017) 198(1):196-204. doi:10.4049/jimmunol.1600420
42. Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep (2016) 6:1-13. doi:10.1038/srep19570
43. Cantisani R, Pezzicoli A, Cioncada R, Malzone C, De Gregorio E, D'Oro U, et al. Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells. J Immunol (2015) 194(4):1717-25. doi:10.4049/jimmunol.1400623
44. Cioncada R, Maddaluno M, Vo HTM, WoodruffM, Tavarini S, Sammicheli C, et al. Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells. PLoS One (2017) 12(10):e0185843. doi:10.1371/journal.pone.0185843
45. Szabo A, Gogolak P, Pazmandi K, Kis-Toth K, Riedl K, Wizel B, et al. The two-component adjuvant IC31® boosts type I interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs. PLoS One (2013) 8(2). doi:10.1371/journal.pone.0055264
46. Sekiya T, Yamagishi J, Gray JHV, Whitney PG, Martinelli A, Zeng W, et al. PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8+T cell responses. Biomaterials (2017) 137:61-72. doi:10.1016/j.biomaterials.2017.05.018
47. Halliday A, Turner JD, Guimarães A, Bates PA, Taylor MJ. The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models. Parasit Vectors (2016) 9(1):1-9. doi:10.1186/s13071-016-1381-0
48. Matsumoto M, Tatematsu M, Nishikawa F, Azuma M, Ishii N, Morii-Sakai A, et al. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat Commun (2015) 6:1-12. doi:10.1038/ncomms7280
49. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest (2010) 120(2):607-16. doi:10.1172/JCI39293
50. Reed SG, Hsu FC, Carter D, Orr MT. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. Curr Opin Immunol (2016) 41:85-90. doi:10.1016/j.coi.2016.06.007
51. Lu Y, Swartz JR. Functional properties of flagellin as a stimulator of innate immunity. Sci Rep (2016) 6:1-11. doi:10.1038/srep18379
52. Buonsanti C, Balocchi C, Harfouche C, Corrente F, Galli Stampino L, Mancini F, et al. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Sci Rep (2016) 6:1-12. doi:10.1038/srep29063
53. Bagnoli F, Fontana MR, Soldaini E, Mishra RP, Fiaschi L, Cartocci E, et al. Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci U S A (2015) 112(12):201424924. doi:10.1073/pnas.1424924112
54. Van Hoeven N, Fox CB, Granger B, Evers T, Joshi SW, Nana GI, et al. A Formulated TLR7/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines. Sci Rep (2017) 7:1-15. doi:10.1038/srep46426
55. Song YC, Liu SJ. A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms. Sci Rep (2015) 5:1-12. doi:10.1038/srep12578
56. Orr MT, Beebe EA, Hudson TE, Moon JJ, Fox CB, Reed SG, et al. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One (2014) 9(1):e83884. doi:10.1371/journal.pone.0083884
57. Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, Sherwood ER. The toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Infect Immun (2011) 79(9):3576-87. doi:10.1128/IAI.00022-11
58. Cui W, Joshi NS, Liu Y, Meng H, Kleinstein SH, Kaech SM. TLR4 ligands lipopolysaccharide and monophosphoryl lipid A differentially regulate effector and memory CD8+ T cell differentiation. J Immunol (2014) 192(9):4221-32. doi:10.4049/jimmunol.1302569
59. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, et al. Co-delivery of cancer-associated antigen and toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+T cell-mediated anti-tumor immunity. Vaccine (2008) 26(39):5046-57. doi:10.1016/j.vaccine.2008.07.035
60. Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol (2001) 2(9):882-8. doi:10.1038/ni0901-882
61. Zanoni I, Granucci F. Regulation and dysregulation of innate immunity by NFAT signaling downstream of pattern recognition receptors (PRRs). Eur J Immunol (2012) 42(8):1924-31. doi:10.1002/eji.201242580
62. Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 17(5):604-9. doi:10.1038/nm.2365
63. Müller MR, Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol (2010) 10(9):645-56. doi:10.1038/nri2818
64. Goodridge HS, Simmons RM, Underhill DM. Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J Immunol (2007) 178(5):3107-15. doi:10.4049/jimmunol.178.5.3107
65. Greenblatt MB, Aliprantis A, Hu B, Glimcher LH. Calcineurin regulates innate antifungal immunity in neutrophils. J Exp Med (2010) 207(5):923-31. doi:10.1084/jem.20092531
66. Yonekawa A, Saijo S, Hoshino Y, Miyake Y, Ishikawa E, Suzukawa M, et al. Dectin-2 is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria. Immunity (2014) 41(3):402-13. doi:10.1016/j.immuni.2014.08.005
67. Herbst S, Shah A, Mazon Moya M, Marzola V, Jensen B, Reed A, et al. Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus. EMBO Mol Med (2015) 7(3):e201404556. doi:10.15252/emmm.201404556
68. Santus W, Barresi S, Mingozzi F, Broggi A, Orlandi I, Stamerra G, et al. Skin infections are eliminated by cooperation of the fibrinolytic and innate immune systems. Sci Immunol (2017) 2(15):eaan2725. doi:10.1126/sciimmunol.aan2725
69. Zanoni I, Spreafico R, Bodio C, Di Gioia M, Cigni C, Broggi A, et al. IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. Cell Rep (2013) 4(6):1235-49. doi:10.1016/j.celrep.2013.08.021
70. Granucci F, Zanoni I, Pavelka N, Van Dommelen SL, Andoniou CE, Belardelli F, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med (2004) 200(3):287-95. doi:10.1084/jem.20040370
71. Zanoni I, Ostuni R, Barresi S, Di Gioia M, Broggi A, Costa B, et al. CD14 and NFAT mediate lipopolysaccharide-induced skin edema formation in mice. J Clin Invest (2012) 122(5):1747-57. doi:10.1172/JCI60688
72. Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol (2006) 176(2):966-73. doi:10.4049/jimmunol.176.2.966
73. Kastenmüller W, Torabi-Parizi P, Subramanian N, Lämmermann T, Germain RN. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell (2012) 150(6):1235-48. doi:10.1016/j.cell.2012.07.021
74. Gonzalez SF, Lukacs-Kornek V, Kuligowski MP, Pitcher LA, Degn SE, Kim YA, et al. Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes. Nat Immunol (2010) 11(5):427-34. doi:10.1038/ni.1856
75. Roozendaal R, Mempel TR, Pitcher LA, Gonzalez SF, Verschoor A, Mebius RE, et al. Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity (2009) 30(2):264-76. doi:10.1016/j.immuni.2008.12.014
76. Gerner MY, Torabi-Parizi P, Germain RN. Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens. Immunity (2015) 42(1):172-85. doi:10.1016/j.immuni.2014.12.024
77. Gerner MY, Kastenmuller W, Ifrim I, Kabat J, Germain RN. Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. Immunity (2012) 37(2):364-76. doi:10.1016/j.immuni.2012.07.011
78. Iannacone M, Moseman EA, Tonti E, Bosurgi L, Junt T, Henrickson SE, et al. Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature (2010) 465(7301):1079-83. doi:10.1038/nature09118
79. Sixt M, Kanazawa N, Selg M, Samson T, Roos G, Reinhardt DP, et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity (2005) 22(1):19-29. doi:10.1016/j.immuni.2004.11.013
80. Farrell HE, Davis-Poynter N, Bruce K, Lawler C, Dolken L, Mach M, et al. Lymph node macrophages restrict murine cytomegalovirus dissemination. J Virol (2015) 89(14):7147-58. doi:10.1128/JVI.00480-15
81. Frederico B, Chao B, Lawler C, May JS, Stevenson PG. Subcapsular sinus macrophages limit acute gammaherpesvirus dissemination. J Gen Virol (2015) 96(8):2314-27. doi:10.1099/vir.0.000140
82. Tomura M, Hata A, Matsuoka S, Shand FH, Nakanishi Y, Ikebuchi R, et al. Tracking and quantification of dendritic cell migration and antigen trafficking between the skin and lymph nodes. Sci Rep (2014) 4:1-11. doi:10.1038/srep06030
83. Kissenpfennig A, Henri S, Dubois B, Laplace-Builhé C, Perrin P, Romani N, et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areasdistinct from slower migrating Langerhans cells. Immunity (2005) 22(5):643-54. doi:10.1016/j.immuni.2005.04.004
84. Radtke AJ, Kastenmüller W, Espinosa DA, Gerner MY, Tse SW, Sinnis P, et al. Lymph-node resident CD8a+ dendritic cells capture antigens from migratory malaria sporozoites and induce CD8+ T cell responses. PLoS Pathog (2015) 11(2):e1004637. doi:10.1371/journal.ppat.1004637
85. Iezzi G, Fröhlich A, Ernst B, Ampenberger F, Saeland S, Glaichenhaus N, et al. Lymph node resident rather than skin-derived dendritic cells initiate specific T cell responses after Leishmania major infection. J Immunol (2006) 177(2):1250-6. doi:10.4049/jimmunol.177.2.1250
86. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev (2004) 199:9-26. doi:10.1111/j.0105-2896.2004.00142.x
87. Thacker RI, Janssen EM. Cross-presentation of cell-associated antigens by mouse splenic dendritic cell populations. Front Immunol (2012) 3:41. doi:10.3389/fimmu.2012.00041
88. Brewitz A, EickhoffS, Dähling S, Quast T, Bedoui S, Kroczek RA, et al. CD8+T cells orchestrate pDC-XCR1+dendritic cell spatial and functional cooperativity to optimize priming. Immunity (2017) 46(2):205-19. doi:10.1016/j.immuni.2017.01.003
89. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity (2006) 25(1):153-62. doi:10.1016/j.immuni.2006.04.017
90. Mount AM, Smith CM, Kupresanin F, Stoermer K, Heath WR, Belz GT. Multiple dendritic cell populations activate CD4+ T cells after viral stimulation. PLoS One (2008) 3(2):e1691. doi:10.1371/journal.pone.0001691
91. Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I, et al. Cross-presentation of viral and self antigens by skin-derived CD103+dendritic cells. Nat Immunol (2009) 10(5):488-95. doi:10.1038/ni.1724
92. Kitano M, Yamazaki C, Takumi A, Ikeno T, Hemmi H, Takahashi N, et al. Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node. Proc Natl Acad Sci U S A (2016) 113(4):1044-9. doi:10.1073/pnas.1513607113
93. Waithman J, Zanker D, Xiao K, Oveissi S, Wylie B, Ng R, et al. Resident CD8+ and migratory CD103+ dendritic cells control CD8 T cell immunity during acute influenza infection. PLoS One (2013) 8(6):e66136. doi:10.1371/journal.pone.0066136
94. Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. Human tissues contain CD141hiCross-presenting dendritic cells with functional homology to mouse CD103+nonlymphoid dendritic cells. Immunity (2012) 37(1):60-73. doi:10.1016/j.immuni.2012.04.012
95. Edelson BT, KC W, Juang R, Kohyama M, Benoit LA, Klekotka PA, et al. Peripheral CD103 + dendritic cells form a unified subset developmentally related to CD8a + conventional dendritic cells. J Exp Med (2010) 207(4):823-36. doi:10.1084/jem.20091627
96. Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, Güttler S, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity (2009) 31(5):823-33. doi:10.1016/j.immuni.2009.08.027
97. Ravindran R, Rusch L, Itano A, Jenkins MK, McSorley SJ. CCR6-dependent recruitment of blood phagocytes is necessary for rapid CD4 T cell responses to local bacterial infection. Proc Natl Acad Sci U S A (2007) 104(29):12075-80. doi:10.1073/pnas.0701363104
98. Van VQ, Lesage S, Bouguermouh S, Gautier P, Rubio M, Levesque M, et al. Expression of the self-marker CD47 on dendritic cells governs their trafficking to secondary lymphoid organs. EMBO J (2006) 25(23):5560-8. doi:10.1038/sj.emboj.7601415
99. Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, Malissen B, et al. Tumor immunotherapy by epicutaneous immunization requires Langerhans cells. J Immunol (2008) 180(3):1991-8. doi:10.4049/jimmunol.180.3.1991
100. Wang L, Bursch LS, Kissenpfennig A, Malissen B, Jameson SC, Hogquist KA. Langerin expressing cells promote skin immune responses under defined conditions. J Immunol (2008) 180(7):4722-7. doi:10.4049/jimmunol.180.7.4722
101. Seneschal J, Jiang X, Kupper TS. Langerin + dermal DC, but not Langerhans cells, are required for effective CD8-mediated immune responses after skin scarification with vaccinia virus. J Invest Dermatol (2014) 134(3):686-94. doi:10.1038/jid.2013.418
102. Kaplan DH. Langerhans cells: not your average dendritic cell. Trends Immunol (2010) 31(12):437. doi:10.1016/j.it.2010.10.003
103. Igyarto BZ, Jenison MC, Dudda JC, Roers A, Müller W, Koni PA, et al. Langerhans cells suppress contact hypersensitivity responses via cognate CD4 interaction and Langerhans cell-derived IL-10. J Immunol (2009) 183(8):5085-93. doi:10.4049/jimmunol.0901884
104. Mutyambizi K, Berger CL, Edelson RL. The balance between immunity and tolerance: the role of Langerhans cells. Cell Mol Life Sci (2009) 66(5):831-40. doi:10.1007/s00018-008-8470-y
105. EickhoffS, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, et al. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell (2015) 162(6):1322-37. doi:10.1016/j.cell.2015.08.004
106. Allenspach EJ, Lemos MP, Porrett PM, Turka LA, Laufer TM. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity (2008) 29(5):795-806. doi:10.1016/j.immuni.2008.08.013
107. Sen D, Forrest L, Kepler TB, Parker I, Cahalan MD. Selective and site-specific mobilization of dermal dendritic cells and Langerhans cells by Th1-and Th2-polarizing adjuvants. Proc Natl Acad Sci U S A (2010) 107(18):8334-9. doi:10.1073/pnas.0912817107
108. Antonialli R, Sulczewski FB, Amorim KNDS, Almeida BDS, Ferreira NS, Yamamoto MM, et al. CpG oligodeoxinucleotides and flagellin modulate the immune response to antigens targeted to CD8a+and CD8a-conventional dendritic cell subsets. Front Immunol (2017) 8:1727. doi:10.3389/fimmu.2017.01727
109. Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials (2015) 40:88-97. doi:10.1016/j.biomaterials.2014.10.053
110. Trumpfheller C, Finke JS, López CB, Moran TM, Moltedo B, Soares H, et al. Intensified and protective CD4 + T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med (2006) 203(3):607-17. doi:10.1084/jem.20052005
111. Boscardin SB, Hafalla JC, Masilamani RF, Kamphorst AO, Zebroski HA, Rai U, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med (2006) 203(3):599-606. doi:10.1084/jem.20051639
112. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med (2004) 199(6):815-24. doi:10.1084/jem.20032220
113. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer (2007) 109(2):170-9. doi:10.1002/cncr.22402
114. Granucci F, Prosperi D. Nanoparticles: "magic bullets" for targeting the immune system. Semin Immunol (2017) 34:1-2. doi:10.1016/j.smim.2017.10.002
115. Prosperi D, Colombo M, Zanoni I, Granucci F. Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases. Semin Immunol (2017) 34:61-7. doi:10.1016/j.smim.2017.08.010
116. Boraschi D, Italiani P, Palomba R, Decuzzi P, Duschl A, Fadeel B, et al. Nanoparticles and innate immunity: new perspectives on host defence. Semin Immunol (2017) 34:33-51. doi:10.1016/j.smim.2017.08.013
117. KantoffPW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 28(7):1099-105. doi:10.1200/JCO.2009.25.0597
118. Yang Z, Xu M, Jia Z, Zhang Y, Wang L, Zhang H, et al. A novel antigen delivery system induces strong humoral and CTL immune responses. Biomaterials (2017) 134:51-63. doi:10.1016/j.biomaterials.2017.04.035
119. Rincon-Restrepo M, Mayer A, Hauert S, Bonner DK, Phelps EA, Hubbell JA, et al. Vaccine nanocarriers: coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses. Biomaterials (2017) 132:48-58. doi:10.1016/j.biomaterials.2017.03.047
120. Kim SY, Noh YW, Kang TH, Kim JE, Kim S, Um SH, et al. Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity. Biomaterials (2017) 130:56-66. doi:10.1016/j.biomaterials.2017.03.034
121. Waeckerle-Men Y, Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev (2005) 57:475-82. doi:10.1016/j.addr.2004.09.007
122. Maji M, Mazumder S, Bhattacharya S, Choudhury ST, Sabur A, Shadab M, et al. A lipid based antigen delivery system efficiently facilitates MHC class-I antigen presentation in dendritic cells to stimulate CD8+T cells. Sci Rep (2016) 6:1-12. doi:10.1038/srep27206
123. Bachem A, Güttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c + CD141 + cells as homologues of mouse CD8 + dendritic cells. J Exp Med (2010) 207(6):1273-81. doi:10.1084/jem.20100348
124. Huysamen C, Willment JA, Dennehy KM, Brown GD. CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes. J Biol Chem (2008) 283(24):16693-701. doi:10.1074/jbc. M709923200
125. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, et al. Characterization of human DNGR-1 + BDCA3 + leukocytes as putative equivalents of mouse CD8a + dendritic cells. J Exp Med (2010) 207(6):1261-71. doi:10.1084/jem.20092618
126. Kroczek RA, Henn V. The role of XCR1 and its ligand XCL1 in antigen cross-presentation by murine and human dendritic cells. Front Immunol (2012) 3:1-5. doi:10.3389/fimmu.2012.00014
127. Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, et al. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood (2012) 119(10):2284-92. doi:10.1182/blood-2011-08-373944
128. Li J, Ahmet F, Sullivan LC, Brooks AG, Kent SJ, De Rose R, et al. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol (2015) 45(3):854-64. doi:10.1002/eji.201445127
129. Caminschi I, Ahmet F, Kitsoulis S, Teh JS, Lo JC, Rizzitelli A, et al. The dendritic cell subtype restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood (2008) 112(8):3264-73. doi:10.1182/blood-2008-05-155176
130. Lahoud MH, Ahmet F, Kitsoulis S, Wan SS, Vremec D, Lee CN, et al. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J Immunol (2011) 187(2):842-50. doi:10.4049/jimmunol.1101176
131. Kato Y, Zaid A, Davey GM, Mueller SN, Nutt SL, Zotos D, et al. Targeting antigen to Clec9A primes follicular Th cell memory responses capable of robust recall. J Immunol (2015) 195(3):1006-14. doi:10.4049/jimmunol.1500767
132. Park H-Y, Light A, Lahoud MH, Caminschi I, Tarlinton DM, Shortman K. Evolution of B cell responses to Clec9A-targeted antigen. J Immunol (2013) 191(10):4919-25. doi:10.4049/jimmunol.1301947
133. Tullett KM, Leal Rojas IM, Minoda Y, Tan PS, Zhang JG, Smith C, et al. Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition. JCI Insight (2016) 1(7):1-12. doi:10.1172/jci.insight.87102
134. Park HY, Tan PS, Kavishna R, Ker A, Lu J, Chan CEZ, et al. Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells. NPJ Vaccines (2017) 2(1):31. doi:10.1038/s41541-017-0033-5
135. Sancho D, Mourão-Sá D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest (2008) 118(6):2098-110. doi:10.1172/JCI34584
136. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature (1995) 375(6527):151-5. doi:10.1038/375151a0
137. Shrimpton RE, Butler M, Morel AS, Eren E, Hue SS, Ritter MA. CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self. Mol Immunol (2009) 46(6):1229-39. doi:10.1016/j.molimm.2008.11.016
138. Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, Chen K, et al. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol (2006) 18(6):857-69. doi:10.1093/intimm/dxl022
139. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol (2000) 151(3):673-83. doi:10.1083/jcb.151.3.673
140. Guo M, Gong S, Maric S, Misulovin Z, Pack M, Mahnke K, et al. A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol (2000) 61(8):729-38. doi:10.1016/S0198-8859(00)00144-0
141. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8 + T cell tolerance. J Exp Med (2002) 196(12):1627-38. doi:10.1084/jem.20021598
142. Tel J, Benitez-Ribas D, Hoosemans S, Cambi A, Adema GJ, Figdor CG, et al. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur J Immunol (2011) 41(4):1014-23. doi:10.1002/eji.201040790
143. Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A (2007) 104(4):1289-94. doi:10.1073/pnas.0610383104
144. Sartorius R, D'Apice L, Trovato M, Cuccaro F, Costa V, De Leo MG, et al. Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response. EMBO Mol Med (2015) 7(7):973-88. doi:10.15252/emmm.201404525
145. Sartorius R, Bettua C, D'Apice L, Caivano A, Trovato M, Russo D, et al. Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants. Eur J Immunol (2011) 41(9):2573-84. doi:10.1002/eji.201141526
146. Caminschi I, Meuter S, Heath WR. DEC-205 is a cell surface receptor for CpG oligonucleotides. Oncoimmunology (2013) 2(3):e23128. doi:10.4161/onci.23128
147. Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol (2002) 158(7):1277-85. doi:10.1083/jcb.200208083
148. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol (2007) 178(7):4169-76. doi:10.4049/jimmunol.178.7.4169
149. Xu H, Zhao G, Huang X, Ding Z, Wang J, Wang X, et al. CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination. J Gene Med (2010) 12(6):97-106. doi:10.1002/jgm.1412
150. Chen J, Zurawski G, Zurawski S, Wang Z, Akagawa K, Oh S, et al. A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40 hematology & oncology. J Hematol Oncol (2015) 8(1):1-15. doi:10.1186/s13045-015-0131-7
151. Mingozzi F, Spreafico R, Gorletta T, Cigni C, Di Gioia M, Caccia M, et al. Prolonged contact with dendritic cells turns lymph node-resident NK cells into anti-tumor effectors. EMBO Mol Med (2016) 8(9):1039-51. doi:10.15252/emmm.201506164
152. Dissanayake D, Murakami K, Tran MD, Elford AR, Millar DG, Ohashi PS. Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant. PLoS One (2014) 9(3):e92380. doi:10.1371/journal.pone.0092380
153. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol (2008) 38:1033-42. doi:10.1002/eji.200737995
154. Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol (2013) 43:2554-65. doi:10.1002/eji.201343324
155. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 361:1838-47. doi:10.1056/NEJMoa0810097
156. Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res (2012) 18:6497-509. doi:10.1158/1078-0432.CCR-12-2189
157. Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, et al. Addition of interferon-a to the p53-SLP V vaccine results in increased production of interferon-c in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer (2013) 132:1581-91. doi:10.1002/ijc.27819
158. Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients T reated for metastatic colorectal cancer. Clin Cancer Res (2009) 15(3):1086-96. doi:10.1158/1078-0432.CCR-08-2227
159. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res (2012) 18(19):5460-70. doi:10.1158/1078-0432.CCR-11-3368
160. Bryson PD, Han X, Truong N, Wang P. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth. Vaccine (2017) 35(43):5842-9. doi:10.1016/j.vaccine.2017.09.017
161. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science (2015) 348(6230):69-74. doi:10.1126/science.aaa4971
162. Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med (2018) 5931(April):1-15. doi:10.1126/scitranslmed.aao5931
163. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature (2017) 547(7662):222-6. doi:10.1038/nature23003
164. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature (2017) 547(7662):217-21. doi:10.1038/nature22991
165. Laxmanan S, Robertson SW, Wang E, Lau JS, David M, Mukhopadhyay D. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun (2005) 334(1):193-8. doi:10.1016/j.bbrc.2005.06.065
166. Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother (2007) 56:761-70. doi:10.1007/s00262-006-0234-7
167. Baghdadi M, Endo H, Takano A, Ishikawa K, Kameda Y, Wada H, et al. High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Sci Rep (2018) 8(1):418. doi:10.1038/s41598-017-18796-8
168. Kao JY, Gong Y, Chen C, Zheng Q-D, Chen J. Tumor-derived TGF-β reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol (2018) 170:3806-11. doi:10.4049/jimmunol.170.7.3806
169. Zhao S, Wu D, Wu P, Wang Z, Huang J. Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis. PLoS One (2015) 10(10):e0139598. doi:10.1371/journal.pone.0139598
170. Oft M. IL-10: master switch from tumor-promoting in flammation to antitumor immunity. Cancer Immunol Res (2014) 2:194-200. doi:10.1158/2326-6066.CIR-13-0214
171. Verronèse E, Delgado A, Valladeau-Guillemond J, Garin G, Guillemaut S, Tredan O, et al. Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. Oncoimmunology (2016) 5(3):e1100791. doi:10.1080/2162402X.2015.1100791
172. Imai K, Minamiya Y, Koyota S, Ito M, Saito H, Sato Y, et al. Inhibition of dendritic cell migration by transforming growth factor-b 1 increases tumor-draining lymph node metastasis. J Exp Clin Cancer Res (2012) 31(3):1-9. doi:10.1186/1756-9966-31-3
173. Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res (2016) 22(9):2155-66. doi:10.1158/1078-0432.CCR-15-2205
174. Anandasabapathy N, Feder R, Mollah S, Tse SW, Longhi MP, Mehandru S, et al. Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. J Exp Med (2014) 211(9):1875-91. doi:10.1084/jem.20131397
175. Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res (2011) 71(19):6132-43. doi:10.1158/0008-5472.CAN-11-0291
176. Perez-Shibayama C, Gil-Cruz C, Nussbacher M, Allgäuer E, Cervantes-Barragan L, Züst R, et al. Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity. PLoS One (2013) 8(11):e81442. doi:10.1371/journal.pone.0081442
177. Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight (2016) 1(10):e87059. doi:10.1172/jci.insight.87059
178. Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Min W, et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer (2013) 132:967-77. doi:10.1002/ijc.27710
179. Mentzer AJ, O'Connor D, Pollard AJ, Hill AVS. Searching for the human genetic factors standing in the way of universally effective vaccines. Philos Trans R Soc Lond B Biol Sci (2015) 370(1671):20140341-20140341. doi:10.1098/rstb.2014.0341
180. Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell (2014) 157(2):499-513. doi:10.1016/j.cell.2014.03.031